Skip to content

Encorafenib

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: braftovi, NVP-LGX818-NXA

OnpFDA approvedPMDA approvedOrphan designationATC L01EC03

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Encorafenib is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 22 molecular targets, including RAF1, BRAF and LIMK1. Recorded indications include BRAF mutation-positive colorectal cancer, Metastatic malignant melanoma and Unresectable malignant melanoma with BRAF gene mutation.

  • Approval status: onp (first approved 2018 by the FDA).
  • Molecular targets: RAF1, BRAF, LIMK1 and PCYT1A (22 listed in DrugCentral).
  • Indications: BRAF mutation-positive colorectal cancer, Metastatic malignant melanoma and Unresectable malignant melanoma with BRAF gene mutation.
  • ATC code: L01EC03 (B-Raf serine-threonine kinase (BRAF) inhibitors).
  • Molecular formula: C22H27ClFN7O4S; molecular weight 540.01 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

  • BRAF mutation-positive colorectal cancer
  • Metastatic malignant melanoma
  • Unresectable malignant melanoma with BRAF gene mutation

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2019-01-08PMDA—Ono Pharmaceutical Co., Ltd.Yes
2018-06-27FDA—ARRAY BIOPHARMA INCYes

ATC classification

ATC codeTherapeutic hierarchy
L01EC03ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › B-Raf serine-threonine kinase (BRAF) inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: HRAS, KRAS, NRAS · Actionable PGx
  • EMA label: BRAF · Testing Required
  • FDA label: BRAF · Testing Required
  • FDA label: HRAS, KRAS, NRAS · Actionable PGx
  • HCSC label: HRAS, KRAS, NRAS · Actionable PGx
  • HCSC label: BRAF · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Serous retinal detachment1948.8
Neoplasm progression837.0
Death314.7
Second primary malignancy256.8
Serous retinopathy255.8
Retinal detachment245.3
Off label use199.3
Pyrexia179.7
Nausea155.4
Melanocytic naevus147.2
Vision blurred138.2
Dermatitis acneiform137.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Encorafenib is on its molecule page.

Molecular formulaC22H27ClFN7O4S
Molecular weight540.01 g/mol
CAS number1269440-17-6
InChIKeyCMJCXYNUCSMDBY-ZDUSSCGKSA-N
PubChem CID50922675
COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Encorafenib used for?

DrugCentral lists the following indications for Encorafenib: BRAF mutation-positive colorectal cancer, Metastatic malignant melanoma and Unresectable malignant melanoma with BRAF gene mutation.

How does Encorafenib work?

Its molecular targets in DrugCentral include RAF1 (inhibitor), BRAF (inhibitor), LIMK1 and PCYT1A.

When was Encorafenib first approved?

Encorafenib was first approved by the FDA in 2018.

What is the chemical formula of Encorafenib?

Encorafenib has the molecular formula C22H27ClFN7O4S and a molecular weight of 540.01 g/mol.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2018-06-27
AgencyFDA
Targets22
Indications3
FormulaC22H27ClFN7O4S
DrugCentral ID5289
Interactive profile